Cetera Investment Advisers
DNA icon

Cetera Investment Advisers’s Ginkgo Bioworks DNA Stock Holding History

Cetera Investment Advisers’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,843
Closed -$64.8K – 3778
2024
Q2 		$64.8K Sell
4,843
-51,760
-91% -$1.54M ﹤0.01% 3570
2024
Q1 		$2.63M Buy
56,603
+54,570
+2,684% +$2.82M 0.01% 1364
2023
Q4 		$137K Buy
2,033
+889
+78% +$54.4K ﹤0.01% 2107
2023
Q3 		$82.8K Buy
1,144
+204
+22% +$16.3K ﹤0.01% 2111
2023
Q2 		$70K Sell
940
-359
-28% -$21.3K ﹤0.01% 2109
2023
Q1 		$69.1K Buy
1,299
+408
+46% +$25.9K ﹤0.01% 2081
2022
Q4 		$60.2K Sell
891
-407
-31% -$37.4K ﹤0.01% 2030
2022
Q3 		$162K Buy
1,298
+952
+275% +$113K ﹤0.01% 1526
2022
Q2 		$33K Buy
+346
New +$42.2K ﹤0.01% 1786

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cetera Investment Advisers's DNA Position: Q3 2024 in Review

Cetera Investment Advisers sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 4,843 shares — an estimated $64.8K sold.

Cetera Investment Advisers first reported a position in DNA in Q2 2022 and held it in 9 quarters. The position peaked at $2.63M in Q1 2024. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Cetera Investment Advisers reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Cetera Investment Advisers sold 4,843 Ginkgo Bioworks shares in Q3 2024, an estimated $64.8K.
  • Cetera Investment Advisers first reported a position in Ginkgo Bioworks in Q2 2022 and held it in 9 quarters.
  • Cetera Investment Advisers's Ginkgo Bioworks position peaked at $2.63M in Q1 2024.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Cetera Investment Advisers's 13F filing for Q3 2024, filed 13 Nov 2024.